go-v.orgdoi

Understanding and Targeting MET Signaling in Solid Tumors - Are We There Yet?

Witthawat Ariyawutyakorn, Siriwimon Saichaemchan, Marileila Varella‐Garcia · Journal of Cancer · 2016

  • DOI 10.7150/jca.12663
  • Publisher Ivyspring International Publisher
  • Type review
  • Issued 2016

Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.

Journal of Cancer · Ivyspring International Publisher · review · 2016

Abstract

The MET signaling pathway plays an important role in normal physiology and its deregulation has proved critical for development of numerous solid tumors. Different technologies have been used to investigate the genomic and proteomic status of MET in cancer patients and its association with disease prognosis. Moreover, with the development of targeted therapeutic drugs, there is an urgent need to identify potential biomarkers for selection of patients who are more likely to derive benefit from these agents.

Unfortunately, the variety of technical platforms and analysis criteria for diagnosis has brought confusion to the field and a lack of agreement in the evaluation of MET status as a prognostic or predictive marker for targeted therapy agents. We review the molecular mechanisms involved in the deregulation of the MET signaling pathway in solid tumors, the different technologies used for diagnosis, and the main factors that affect the outcome, emphasizing the urge for completing analytical and clinical validation of these tests. We also review the current clinical studies with MET targeted agents, which mostly focus on lung cancer.

Open the resolved locator · 10.7150/jca.12663

Metadata licence: OpenAlex metadata (CC0)

Registry
OpenAlex DOI index + API
Fetched
2026-11-19 20:54 UTC
Cache state
not cached yet (bulk-index+openalex)
Locator
https://www.jcancer.org/v07p0633.htm
Metadata licence
OpenAlex metadata (CC0)
Scope
Metadata as returned by the resolver; abstracts are never generated here.